Optimi Health Corp. (Nasdaq: OPTH) announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE